Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis1 by Burman, William J. et al.
The role of microbial factors in outcomes of tubercu-
losis treatment has not been well studied. We performed a 
case–control study to evaluate the association between a 
Beijing strain and tuberculosis treatment outcomes. Isolates 
from patients with culture-positive treatment failure (n = 8) 
or relapse (n = 54) were compared with isolates from ran-
domly selected controls (n = 296) by using spoligotyping. 
Patients with Beijing strains had a higher risk for relapse 
(odds ratio [OR] 2.0, 95% confidence interval [CI] 1.0–4.0, 
p = 0.04) but not for treatment failure. Adjustment for fac-
tors previously associated with relapse had little effect on 
the association between Beijing strains and relapse. Beijing 
strains were strongly associated with relapse among Asian–
Pacific Islanders (OR 11, 95% CI 1.1–108, p = 0.04). Active 
disease caused by a Beijing strain was associated with in-
creased risk for relapse, particularly among Asian–Pacific 
Islanders.
A
pproximately  2%–5%  of  patients  with  tuberculosis 
(TB)  treated  with  contemporary  short-course  treat-
ment either fail to respond to therapy or recurrent TB can 
develop in these patients after they complete therapy, de-
spite assurance of adherence through supervised treatment 
(1,2). In settings with a high prevalence of disease, a sub-
stantial percentage of recurrent cases are caused by rein-
fection with another strain of Mycobacterium tuberculosis 
(3,4). However, reinfection is an uncommon cause of re-
current disease in settings in which the prevalence of active 
TB is low (5). Several studies have evaluated risk factors 
for recurrent TB, which are severity of the radiographic 
manifestations of disease (presence of cavitation [1,6–8], 
extent of pulmonary involvement [1,6,8], or the presence of 
silicosis [9]), microbial load at diagnosis (7), and 2-month 
sputum culture positivity as an indicator of the early re-
sponse to therapy (1,6,7).
Whether aspects of the infecting strain of M. tuber-
culosis might affect treatment outcomes has not been well 
studied. Studies early in the time of chemotherapy found 
that M. tuberculosis strains from patients who responded 
well to isoniazid monotherapy seemed to be somewhat less 
virulent in a guinea pig model of active TB (10). However, 
this line of investigation was not pursued in the context of 
response to multidrug therapy. DNA fingerprinting tech-
niques  enable  classification  of  M.  tuberculosis  isolates 
into genotype families. The Beijing genotype family has 
received considerable attention because of its association 
with drug resistance (11,12). Furthermore, the Beijing fam-
ily may be rapidly spreading in some areas (13–15). Studies 
from Vietnam (16) and Singapore (17) showed that active 
disease caused by a Beijing strain was associated with an 
increased risk for recurrent TB after completion of treat-
ment.
Recent studies have shown associations among M. tu-
berculosis strains, geographic regions, and human popula-
tions, which suggest that specific strains of M. tuberculosis 
coevolved with human subpopulations (18–20). However, 
with increased population mobility, there has been greater 
mixing of M. tuberculosis strains and human subpopula-
tions. The interaction between these factors (the bacillary 
strain and the race/ethnic background of the patient), may 
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affect response to TB treatment (21). We used isolates from 
a large multicenter clinical trial (Tuberculosis Trials Con-
sortium [TBTC] Study 22) (1) to evaluate the association 
between active disease caused by a Beijing strain and TB 
treatment outcomes. We also explored whether this asso-
ciation was affected by the race/ethnicity of the patient.
Methods
Study Population
TBTC  Study  22  was  a  randomized  trial  compar-
ing once-a-week rifapentine plus isoniazid with twice-a-
week rifampin plus isoniazid during the last 4 months of 
short-course treatment for drug-susceptible pulmonary TB 
(1,22). Adults were enrolled from sites in the United States 
and Canada from 1995 through 1998. Before enrollment, 
all patients had completed an initial 2 months of treatment 
with isoniazid, rifampin, pyrazinamide, and ethambutol (or 
streptomycin). All TB treatment was supervised (directly 
observed therapy).
Sputum cultures were obtained monthly during treat-
ment. Failure was defined as a positive culture >4 months 
of  treatment.  Relapse  was  defined  as  a  positive  culture 
during the 2-year follow-up after completion of therapy. 
Paired isolates from the time of enrollment and the time of 
suspected treatment failure or relapse underwent insertion 
sequence (IS) 6110 fingerprinting (1,23), and an endpoint 
review committee determined whether the positive culture 
was caused by cross-contamination, relapse, or reinfection. 
TBTC Study 22 was reviewed and approved by the Institu-
tional Review Boards of CDC and participating sites. The 
present analysis of isolates from that study was reviewed 
and found to be research that did not include human pa-
tients.
Selection of Case-Patients and Controls
We evaluated the association between active disease 
caused by a Beijing strain and TB treatment outcomes by 
using a nested case–control study of isolates from partici-
pants in TBTC Study 22. Because it is likely that the risk 
factors for treatment failure and relapse are different among 
persons with HIV co-infection, we limited this case–control 
analysis to HIV-negative participants (n = 1,004). Case-pa-
tients were participants who adhered to study therapy and 
had culture-positive treatment failure or relapse caused by 
the initial infecting strain of M. tuberculosis. Controls were 
selected through simple random sampling of participants 
who completed treatment and had 2 years of follow-up (3, 
6, 9, 12, 18, and 24 months after treatment completion) 
with  no  clinical  or  microbiologic  evidence  of  treatment 
failure or relapse. Cases and controls were not matched for 
any demographic, clinical, or radiographic characteristics.
Laboratory Methods
Isolates  from  cases  and  controls  underwent  spoli-
gotyping (24) as modified by Cowan et al. (25). Beijing 
strains were defined as isolates with a spoligotype show-
ing the absence of spacers 1–34 and presence of at least 3 
spacers among spacers 35–43 (26,27). To evaluate possible 
associations between M. tuberculosis lineages, as defined 
by large sequence polymorphisms and treatment outcomes, 
isolates were assigned by spoligotype pattern to previously 
described lineages (20,21).
Statistical Analyses
The number of cases was determined from the parent 
clinical trial; 4 controls were randomly selected for each 
case. Race/ethnicity was determined by site staff who used 
categories defined in the United States TB surveillance sys-
tem (28).
The  definitions  and  primary  objective  of  this  case–
control analysis were formulated before data analysis. The 
initial  analysis  evaluated  the  association  between  active 
disease caused by a Beijing strain and treatment failure 
or relapse. To enable comparisons with previous studies 
(16,17), we then analyzed relapse alone as the outcome. 
We subsequently analyzed the relationships between race/
ethnicity, active disease caused by a Beijing strain, and 
treatment outcomes. Associations between active disease 
caused by a Beijing strain and baseline characteristics and 
treatment outcomes were evaluated by using χ2 analysis. 
Associations  with  treatment  outcomes  were  adjusted  in 
multivariate logistic regression models for factors previ-
ously  associated  with  failure  and  relapse.  These  factors 
were white race, being underweight, pulmonary cavitation, 
bilateral pulmonary involvement, and 2-month sputum cul-
ture positivity (1). Because having been randomly assigned 
rifapentine as treatment was associated with an increased 
risk for relapse in univariate analyses of TBTC Study 22 
(1), we conducted a secondary analysis in which treatment 
assignment was forced into multivariate models of risk for 
poor treatment outcomes.
Results
Of  the  1,004  HIV-negative  participants  in  TBTC 
Study 22, there were 8 instances of treatment failure and 
61 cases of relapse. Of these 69 cases of adverse TB treat-
ment outcomes, isolates from 64 patients were successfully 
genotyped (Figure). Of the 930 study participants who did 
not experience treatment failure or relapse, 76 did not com-
plete therapy and 172 did not complete follow-up. Of the 
remaining 687 patients, 296 (43%) were randomly selected 
as controls for this analysis; their 296 baseline isolates were 
successfully genotyped (Figure).
Demographic and clinical characteristics of cases and 
controls are provided in Table 1. As in the entire study 
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cohort, white race, being underweight, pulmonary cavita-
tion, bilateral pulmonary involvement, and 2-month spu-
tum smear and culture positivity were associated with an 
increased risk for treatment failure and relapse among the 
participants  of  this  case–control  analysis  (Table  1).  Pa-
tients with active disease caused by a Beijing strain had 
an increased risk for treatment failure or relapse (15 [23%] 
of 64 cases vs. 42 [14%] of 296 controls; odds ratio [OR] 
1.9, 95% confidence interval [CI] 0.9–3.6, p = 0.07). When 
analyzed as separate endpoints (Table 2), treatment failure 
was not associated with active disease caused by a Beijing 
strain (OR 0.9, 95% CI 0.1–7.2, p = 1.00), but relapse was 
significantly associated (OR 2.0, 95% CI 1.0–4.0, p = 0.04). 
Active disease caused by the Indo-Oceanic lineage was as-
sociated with a lower risk for treatment failure or relapse, 
although the small number of isolates from that lineage (n = 
25) and the lack of any cases of treatment failure or relapse 
among patients with active disease caused by this lineage 
precluded further evaluation of this association.
Adjustment for the 5 clinical, radiographic, and micro-
biologic risk factors for treatment failure and relapse in the 
parent study had little effect on the OR of active disease 
being caused by a Beijing strain and relapse (adjusted OR 
2.2, 95% CI 1.0–5.0, p = 0.05) (Table 3). Similarly, treat-
ment assignment (rifapentine vs. rifampin) had little effect 
in a multivariate model into which this factor was forced 
(adjusted OR for active disease caused by Beijing strain 
2.3; 95% CI 1.0–5.3, p = 0.04).
We next evaluated the effect of race/ethnicity on the 
association between relapse and active disease caused by a 
Beijing strain (Table 4). Asian–Pacific Islanders were not 
at increased risk for relapse in the entire TBTC Study 22 
cohort or in this nested case–control analysis (OR 0.6, 95% 
CI 0.2–1.4, p = 0.23). However, Asian–Pacific Islanders 
who had active disease caused by a Beijing strain were at 
increased risk for relapse (OR 11, 95% CI 1.0–108, p = 
0.04) (Table 4).
We further evaluated the association between relapse 
and active disease caused by a Beijing strain among race/
ethnicity groups by using stratified analysis. In an analysis 
limited to Asian–Pacific Islanders, adjustment for other risk 
factors for relapse had little effect on the association be-
tween relapse and active disease caused by a Beijing strain 
(adjusted OR 15.8, 95% CI 1.3–192, p = 0.03) (Table 5). 
Among other race/ethnicity groups, there was no associa-
tion between relapse and active disease caused by a Beijing 
strain (Table 5).
Discussion
Using isolates from participants in a large prospective 
trial of supervised intermittent treatment, we found that 
active disease caused by a Beijing strain of M. tuberculo-
sis was associated with a 2-fold increased risk for adverse 
TB treatment outcomes. The relationship between Beijing 
strains and treatment outcomes was driven by relapse be-
cause of their greater frequency and an apparent lack of any 
association between Beijing strains and treatment failure. 
Adjustment for the clinical, radiographic, and microbio-
logic risk factors for treatment failure and relapse and for 
treatment assignment in TBTC Study 22 had little effect on 
the association between active disease caused by a Beijing 
strain and the risk for relapse. In an exploratory analysis of 
the relationships of the effect of race/ethnicity on the as-
sociation between Beijing strains and treatment outcomes, 
Asian–Pacific Islander patients were at increased risk for 
relapse if they had active disease caused by a Beijing strain, 
albeit with wide CIs around the risk estimate (adjusted OR 
13.9, 95% CI 1.3–164).
Two other studies have evaluated the association be-
tween the Beijing genotype and relapse. A case–control 
analysis from Vietnam reported an adjusted OR of 3.2 for 
treatment failure or relapse among patients with active dis-
ease caused by a Beijing strain (16), and a cohort study 
from Singapore found an adjusted OR of 2.64 for relapse 
associated with Beijing strains (17). Our study provides 
additional support for the hypothesis that active disease 
caused by a Beijing strain is associated with increased risk 
for relapse (adjusted OR 2.2, 95% CI 1.0–4.9). The use of 
a nested case–control analysis of carefully characterized 
patients in a clinical trial enabled us to evaluate the rela-
tionship between Beijing strains and treatment outcomes 
in analyses adjusted for host factors previously associated 
with an increased risk for relapse. We were also able to 
eliminate  effects  of  other  possible  confounding  factors, 
such as treatment duration and adherence to treatment. Ad-
ditionally, because reinfection could obscure the relation-
ship between infection with a Beijing strain and the risk for 
relapse, we were able to remove cases of reinfection from 
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Enrolled
(n = 1,004)
Clinical relapse (n = 2)
or failure after 
nonadherence (n = 3)
Isolate genotyped 
as a case
Failure (n = 8)
Relapse (n = 56)
Culture-positive 
treatment failure (n = 8) 
or relapse (n = 61), with 
adherence to therapy
Isolate not available 
or genotyping 
unsuccessful (n = 5)
Did not complete 
assigned therapy (n = 72)
Did not complete 2-year 
follow-up (n =  172)
Not selected as 
a control
(n = 389)
Randomly selected as 
a control (n = 296)
Isolate not available 
or genotyping 
unsuccessful (n = 0)
Successfully 
genotyped as a 
control (n = 296)
No failure/relapse
(n = 930)
Eligible for selection as 
control  (n = 686)
Figure. Selection of case-patients and controls, Tuberculosis Trials 
Consortium Study 22. The Tuberculosis Trials Consortium Study 
enrolled patients during 1995–1998. Participants in the case–control 
study were selected from among 1,004 HIV-infected participants.RESEARCH
this analysis. That adjustment for other risk factors for re-
lapse, such as pulmonary cavitation and being underweight, 
had little effect on the association is additional evidence 
that active disease caused by a Beijing strain increases the 
risk for relapse.
After evolving in eastern Asia, the Beijing family of 
M. tuberculosis has spread around the world (26,29). Why 
might active disease caused by a Beijing strain confer an in-
creased risk for relapse? Laboratory studies have suggested 
that Beijing strains may be better adapted for intracellular 
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Table 1. Characteristics of case-patients and controls, Tuberculosis Trials Consortium Study 22* 
Characteristic
Case-patients (treatment 
failure or relapse), n = 64† 
Controls (patients 
cured), n = 296† 
Odds ratio (95% 
confidence interval)  p value 
Demographic 
  Age, y, mean (SD)  42 (13)  44 (14)  1.0 (0.97–1.01)  0.51
  Men  54 (84)  214 (72)  2.1 (1.0–4.3)  0.05
Treatment 
  Rifapentine, 1×/wk  40 (63)  151 (51)  1.6 (0.9–2.8)  0.10
  Rifampin, 2×/wk  24 (37)  145 (49) 
Ethnic origin 
  Non-Hispanic white  22 (34)  43 (15)  3.1 (1.7–5.7)  0.0002
  Non-Hispanic black  25 (39)  127 (43)  0.9 (0.5–1.5)  0.57
  Hispanic  9 (14)  71 (24)  0.5 (0.2–1.1)  0.08
  Asian–Pacific Islander  6 (9) 45 (15)  0.6 (0.2–1.4)  0.23
  Native American  2 (3)  10 (3)  0.9 (0.2–4.3)  0.92
Birthplace
  United States or Canada  48 (75)  200 (68)  1.4 (0.8–2.7)  0.24
  Mexico  5 (8)  36 (12)  0.6 (0.2–1.6)  0.32
  Europe  2 (3)  4 (1)  2.4 (0.4–13.1)  0.31
  Southeast Asia  2 (3)  6 (2)  1.6 (0.3–7.9)  0.59
  Western Pacific  4 (6)  33 (11)  0.5 (0.2–1.6)  0.24
  Other  3 (5)  17 (6)  0.8 (0.2–2.8)  0.74
Baseline clinical features 
  Fever  50/62 (81)  166/289 (57)  3.1 (1.6–6.0)  0.0007
  Sweats  42/63 (67)  162/287 (56)  1.5 (0.9–2.7)  0.14
  Cough  61 (95)  256/294 (87)  3.0 (0.9–10.1)  0.06
  Underweight‡  38 (59)  82 (28)  3.8 (2.2–6.7)  <0.0001
  Sputum smear positive  55 (86)  193/292 (66)  3.1 (1.5–6.6)  0.002
Baseline chest radiographic features 
  Cavitation  54 (84)  146/287 (51)  5.2 (2.6–10.6)  <0.0001
  Bilateral pulmonary involvement  50 (78)  155/293 (53)  3.2 (1.7–6.0)  0.0002
Two-month sputum analysis 
  Smear positive  16 (25)  30/285 (11)  2.8 (1.4–5.6)  0.002
  Culture positive  33 (54)  48/267 (18)  5.4 (3.0–9.7)  <0.0001
Mycobacterium tuberculosis lineage/family 
  East Asian/Beijing  15 (23)  42 (14)  1.9 (0.9–3.6)  0.07
  Euro-American  47 (73)  221 (75)  0.9 (0.5–1.7)  0.84
  Indo-Oceanic  0 25 (8.5)  0.08 (0.01–1.4)  0.01
  East African  1 (1.6)  3 (1.0)  1.6 (0.16–15.1)  0.54
  Unclassified lineage  1 (1.6)  5 (1.7)  0.9 (0.11–8.04)  1.00
*The Tuberculosis Trials Consortium Study enrolled patients during 1995–1998. Participants in the case–control study were selected from among 1,004  
HIV-infected participants. 
†Except for age, values are no. (%) or no. positive/no. tested (%). 
‡Less than 10% below ideal bodyweight at diagnosis. 
Table 2. Association between treatment failure or relapse and active disease caused by Beijing vs. other genotypes of Mycobacterium 
tuberculosis, Tuberculosis Trials Consortium Study 22* 
Outcome
Disease caused by Beijing 
genotype, n = 57 
Disease caused by other 
genotype, n = 303  Odds ratio (95% CI)  p value 
Cure (n = 296)  42 (14)  254 (86)  1.9 (0.9–3.6)  0.07
Failure or relapse (n = 64)  15 (23)  49 (77) 
  Failure (n = 8)  1 (13)  7 (88)  0.9 (0.1–6.3)  1.00
  Relapse (n = 56)  14 (25)  42 (75)  2.0 (1.0–4.0)  0.04
*The Tuberculosis Trials Consortium Study enrolled patients during 1995–1998. Participants in the case–control study were selected from among 1,004 
HIV-infected participants. CI, confidence interval. Relapse and Beijing Strain of M. tuberculosis
growth (30,31) and are more virulent in animal models of 
TB, perhaps by evading immune responses (32,33). Fur-
thermore, an altered DNA repair enzyme in Beijing isolates 
that confers a mutator phenotype may confer greater flex-
ibility to respond to adverse conditions (34), such as those 
posed by multidrug therapy.
The  possibility  that  Beijing  strains  evade  immune 
responses and are more virulent is generally borne out in 
studies with humans. The Beijing family is associated with 
extrapulmonary TB (35,36). That Beijing strains have been 
implicated in many outbreaks of TB suggests that they may 
be more efficiently transmitted or have an enhanced abil-
ity to progress to active disease than do other strains. In a 
study in Russia, active disease caused by a Beijing strain 
was associated with more severe radiographic manifesta-
tions of pulmonary TB (11). However, 2 smaller studies 
did not find an association between Beijing strains and ra-
diographic severity of pulmonary TB (37,38). Because of 
its case–control design, our study cannot directly address 
the unresolved question of whether active disease caused 
by a Beijing strain is associated with radiographic severity 
of disease (such a comparison would require a cohort study 
design). However, adjustment for cavitation and bilateral 
pulmonary involvement did not affect the association be-
tween Beijing strains and relapse in our study. This find-
ing suggests that the mechanism of the association between 
Beijing strains and relapse is not mediated by radiographic 
severity of disease.
Our study suggests that the increased risk for relapse 
associated with active disease caused by a Beijing strain 
may be related to the race/ethnicity of the patient; risk for 
relapse was higher for persons of Asian–Pacific Islander 
descent. There was also a trend toward increased risk for 
relapse among black patients infected with a Beijing strain, 
according to univariate analysis (OR 2.9, 95% CI 1.0–8.5; 
p = 0.07), although this trend was not retained in adjusted 
analysis (Table 5). It is notable that the population in which 
the Beijing genotype conferred the greatest risk for relapse 
was of Asian–Pacific Islander race/ethnicity and that the 
Beijing genotype evolved in eastern Asia. Coevolution of 
the Beijing genotype among persons of East Asian descent 
may have selected factors that contribute to transmissibility 
and a decreased response to therapy.
Our study has at least 4 limitations. First, the cohort 
from which this nested case–control analysis was drawn 
was composed of patients who enrolled in a randomized 
trial, who differed from the broader patient population at 
study sites. One clear bias in the study population is that 
TBTC Study 22 was limited to patients with drug-suscep-
tible TB. Therefore, we cannot evaluate the association be-
tween Beijing strains and drug resistance. Second, despite 
the size of the study cohort, our case–control analysis had 
limited statistical power to detect associations, particularly 
in  exploratory  analyses  of  the  relationships  between  M. 
tuberculosis genotype, race/ethnicity of the host, and the 
risk for relapse. Third, race/ethnicity was defined by using 
broad categories developed for the United States census and 
used in the TB surveillance system. However, these catego-
ries are crude approximations of the genetic background of 
patients. For example, the category Asian–Pacific Islander 
includes several distinct ethnic groups that have substantial 
differences in genetic backgrounds. We did not have access 
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Table 3. Association between active disease caused by a Beijing genotype of Mycobacterium tuberculosis and relapse, adjusted for 
clinical risk factors, Tuberculosis Trials Consortium Study 22* 
Univariate analysis  Multivariate analysis 
Characteristic Odds ratio (95% CI)  p value  Odds ratio (95% CI)  p value 
Infected with Beijing genotype  2.0 (1.0–4.0)  0.05 2.2 (1.0–4.9)  0.07
Non-Hispanic white race/ethnicity  3.3 (1.7–6.1)  <0.01 3.0 (1.4–6.7)  <0.01
Underweight at tuberculosis diagnosis  4.7 (2.6–8.6)  <0.01 3.7 (1.8–7.2)  <0.01
Pulmonary cavitation  5.0 (2.4–10.7)  <0.01 3.2 (1.4–7.5)  0.01
Bilateral pulmonary disease  2.9 (1.5–5.7)  <0.01 1.8 (0.9–4.0)  0.12
Two-month sputum culture positivity  4.7 (2.6–8.7)  <0.01 2.4 (1.2–4.9)  0.01
*The Tuberculosis Trials Consortium Study enrolled patients during 1995–1998. Participants in the case–control study were selected from among 1,004 
HIV-infected participants. CI, confidence interval. 
Table 4. Association between active disease caused by a Beijing genotype of Mycobacterium tuberculosis and relapse, by racial/ethnic 
background, Tuberculosis Trials Consortium Study 22* 
Patients with disease that relapsed 
Race/ethnicity 
Infected with a Beijing strain, 
no. positive/no. tested (%) 
Not infected with a Beijing strain, 
no. positive/no. tested (%) 
Relapse
odds ratio 
(95% CI)  p value 
Non-Hispanic white (n = 63)  3/11 (27)  17/52 (33)  0.8 (0.2–3.3)  0.73
Non-Hispanic black (n = 148)  6/22 (27)  15/126 (12)  2.8 (0.9–8.2)  0.06
Hispanic (n = 79)  1/7 (14)  7/72 (9.7)  1.5 (0.2–15)  0.70
Asian–Pacific Islander (n = 50)  4/16 (25)  1/34 (2.9)  11 (1.1–108)  0.04
*The Tuberculosis Trials Consortium Study enrolled patients during 1995–1998. Participants in the case–control study were selected from among 1,004  
HIV-infected participants. Participants of Native American race/ethnicity (n = 12) were not included because none were infected with a Beijing strain;  
2 Native American participants had disease that relapsed. CI, confidence interval. RESEARCH
to human genetic material that would enable precise delin-
eation of the genetic backgrounds of the trial’s participants. 
Fourth, we did not adjust for multiple comparisons, and 
our study should be viewed as an exploratory, hypothesis-
generating analysis.
In summary, our study offers additional evidence that 
a common genotype of M. tuberculosis, the Beijing family, 
is associated with increased risk for relapse after comple-
tion of supervised short-course TB treatment. The finding 
that the population at greatest risk for relapse if they had 
active disease caused by a Beijing genotype was persons 
of Asian–Pacific Islander race/ethnicity suggests that the 
coevolution of this bacterial strain and the human popula-
tion may have selected factors that confer a poor response 
to therapy.
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